Engimata is honored to present its research titled "A Versatile Room Temperature Stable Lipid Nanoparticle COVID-19 Protein-Based Vaccine." Join us on Monday, October 23, 2023, from 3:30 PM – 4:30 PM ET at Poster Number: M1530-02-08.
Special Note: Our poster has also been chosen for a unique collection and will have an additional presentation on Oct 24th.
Engimata is an early stage biopharma company located in the San Francisco Bay Area. Engimata has developed a COVID-19 vaccine, using its platform nano lipid particle technology with recombinant viral surface proteins to mimic those found on the SARS-CoV-2 coronavirus particle.